Side-by-side comparison of AI visibility scores, market position, and capabilities
Phoenix AZ copper/gold mining leader (NYSE: FCX) ~$25.4B FY2024 revenue; Grasberg world's largest gold mine, 4.2B lbs copper, EV/AI demand structural tailwind, Kathleen Quirk CEO 2024 competing with BHP and Glencore.
Freeport-McMoRan Inc. is a Phoenix, Arizona-based mining company — publicly traded on the New York Stock Exchange (NYSE: FCX) as an S&P 500 Materials component — operating copper, gold, and molybdenum mines across North America, South America, and Indonesia, including the Grasberg mine complex in Papua, Indonesia (the world's largest gold mine and second-largest copper mine), the Cerro Verde mine in Arequipa, Peru, the Morenci mine in Arizona, and the El Abra mine in Chile through approximately 27,000 employees. In fiscal year 2024, Freeport-McMoRan reported revenues of approximately $25.4 billion, with copper representing the primary revenue driver (producing 4.2 billion pounds of copper at an average realized price of approximately $4.20/lb — the highest sustained copper price since 2011 as AI infrastructure, energy transition, and EV adoption created structural demand growth expectations). CEO Kathleen Quirk assumed the CEO role in June 2024 following Richard Adkerson's retirement after 24 years leading Freeport through the privatization of Freeport-McMoRan from its 2007 Phelps Dodge acquisition through the commodity supercycle, oil price-induced near-bankruptcy in 2016, and recovery to peak copper demand leadership. Freeport's Grasberg Complex (producing 1.7 billion pounds of copper and 1.6 million troy ounces of gold annually at full production) represents the defining asset — transitioning from the Grasberg open pit (the world's largest truck-shovel copper operation, mining ore since the 1980s, reaching pit depletion) to the underground Big Gossan, Grasberg Block Cave, and Deep MLZ block caving mines that provide 40+ years of underground copper production from the same ore body.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.